The US FDA has approved Yescarta, Kite's CAR-T cell therapy, for initial treatment in adults with large B-cell lymphoma (LBCL) that is refractory to one prior therapy or that relapses within 12 months of first-line chemoimmunotherapy.
HTTPS://WWW.BIOPHARMA-REPORTER.COM/ARTICLE/2022/04/04/MILESTONE-APPROVAL-FOR-KITE-CAR-T-CELL-THERAPY